Cas:344779-09-5 1-piperidin-4-yl-1,4-diazepan-5-one manufacturer & supplier

We serve Chemical Name:1-piperidin-4-yl-1,4-diazepan-5-one CAS:344779-09-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

1-piperidin-4-yl-1,4-diazepan-5-one

Chemical Name:1-piperidin-4-yl-1,4-diazepan-5-one
CAS.NO:344779-09-5
Synonyms:1-piperidin-4-yl-1,4-diazepan-5-one
Molecular Formula:C10H19N3O
Molecular Weight:197.27700
HS Code:2933990090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:384.88ºC at 760 mmHg
Density:1.072
Index of Refraction:
PSA:44.37000
Exact Mass:197.15300
LogP:0.15580

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 1-piperidin-4-yl-1,4-diazepan-5-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-piperidin-4-yl-1,4-diazepan-5-one physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-piperidin-4-yl-1,4-diazepan-5-one Use and application,1-piperidin-4-yl-1,4-diazepan-5-one technical grade,usp/ep/jp grade.


Related News: AstraZeneca Plc said on Monday that its cancer drug met the main goal of delaying the progression of a form of lung cancer. 1-piperidin-4-yl-1,4-diazepan-5-one manufacturer There is fierce competition for bulk APIs and overcapacity. However, some high-profit, small-scale drugs still have a good market space. 1-piperidin-4-yl-1,4-diazepan-5-one supplier Among the APIs we produce, there is an API which passes through over ten kinds of intermediates in a process when it changes from being a raw material into an API. 1-piperidin-4-yl-1,4-diazepan-5-one vendor Among the APIs we produce, there is an API which passes through over ten kinds of intermediates in a process when it changes from being a raw material into an API. 1-piperidin-4-yl-1,4-diazepan-5-one factory There is fierce competition for bulk APIs and overcapacity. However, some high-profit, small-scale drugs still have a good market space.